HRP20251267T1 - Tekuće formulacije glukagonskih analoga - Google Patents

Tekuće formulacije glukagonskih analoga

Info

Publication number
HRP20251267T1
HRP20251267T1 HRP20251267TT HRP20251267T HRP20251267T1 HR P20251267 T1 HRP20251267 T1 HR P20251267T1 HR P20251267T T HRP20251267T T HR P20251267TT HR P20251267 T HRP20251267 T HR P20251267T HR P20251267 T1 HRP20251267 T1 HR P20251267T1
Authority
HR
Croatia
Prior art keywords
concentration
present
formulation
buffer
hypoglycemia
Prior art date
Application number
HRP20251267TT
Other languages
English (en)
Croatian (hr)
Inventor
Jesper Skodborg VILLADSEN
Tine Elisabeth Gottschalk Bøving
Original Assignee
Zealand Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma A/S filed Critical Zealand Pharma A/S
Publication of HRP20251267T1 publication Critical patent/HRP20251267T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20251267TT 2020-03-16 2021-03-16 Tekuće formulacije glukagonskih analoga HRP20251267T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20163408 2020-03-16
PCT/EP2021/056651 WO2021185821A1 (en) 2020-03-16 2021-03-16 Liquid formulations of glucagon analogues
EP21712156.5A EP4121003B1 (en) 2020-03-16 2021-03-16 Liquid formulations of glucagon analogues

Publications (1)

Publication Number Publication Date
HRP20251267T1 true HRP20251267T1 (hr) 2025-12-05

Family

ID=70008261

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20251267TT HRP20251267T1 (hr) 2020-03-16 2021-03-16 Tekuće formulacije glukagonskih analoga

Country Status (22)

Country Link
US (2) US20210283053A1 (https=)
EP (1) EP4121003B1 (https=)
JP (1) JP7834025B2 (https=)
CN (1) CN115279341B (https=)
AR (1) AR121581A1 (https=)
AU (1) AU2021236878B2 (https=)
BR (1) BR112022018462A2 (https=)
CA (1) CA3171184A1 (https=)
CL (1) CL2022002472A1 (https=)
CO (1) CO2022014452A2 (https=)
ES (1) ES3041327T3 (https=)
HR (1) HRP20251267T1 (https=)
HU (1) HUE073401T2 (https=)
IL (1) IL295977A (https=)
MX (1) MX2022011227A (https=)
PE (1) PE20230258A1 (https=)
PH (1) PH12022552457A1 (https=)
PL (1) PL4121003T3 (https=)
RS (1) RS67245B1 (https=)
TW (1) TW202200190A (https=)
UA (1) UA129439C2 (https=)
WO (1) WO2021185821A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI880227B (zh) * 2022-05-30 2025-04-11 丹麥商西蘭製藥公司 澱粉素類似物之液體調配物
WO2025056677A1 (en) 2023-09-15 2025-03-20 Zealand Pharma A/S Dasiglucagon for use in the treatment of congenital hyperinsulinism

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CN102933598A (zh) 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
IN2015DN00544A (https=) * 2012-07-23 2015-06-26 Zealand Pharma As
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
BR112017014994B1 (pt) 2015-02-17 2023-12-19 Eli Lilly And Company Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal
WO2017053822A1 (en) 2015-09-23 2017-03-30 Behavioral Recognition Systems, Inc. Detected object tracker for a video analytics system
GB201710822D0 (en) 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia
US20190275110A1 (en) 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid

Also Published As

Publication number Publication date
NZ791927A (en) 2025-09-26
PE20230258A1 (es) 2023-02-07
CO2022014452A2 (es) 2022-10-21
EP4121003A1 (en) 2023-01-25
PL4121003T3 (pl) 2026-02-23
WO2021185821A1 (en) 2021-09-23
AU2021236878A1 (en) 2022-09-29
CL2022002472A1 (es) 2023-02-17
JP2023518052A (ja) 2023-04-27
ES3041327T3 (en) 2025-11-11
PH12022552457A1 (en) 2023-12-11
TW202200190A (zh) 2022-01-01
EP4121003B1 (en) 2025-08-06
CA3171184A1 (en) 2021-09-23
US20210283053A1 (en) 2021-09-16
JP7834025B2 (ja) 2026-03-23
BR112022018462A2 (pt) 2022-11-01
IL295977A (en) 2022-10-01
AU2021236878B2 (en) 2025-09-11
EP4121003C0 (en) 2025-08-06
UA129439C2 (uk) 2025-04-23
AR121581A1 (es) 2022-06-15
RS67245B1 (sr) 2025-10-31
CN115279341A (zh) 2022-11-01
CN115279341B (zh) 2026-03-31
MX2022011227A (es) 2022-10-07
HUE073401T2 (hu) 2026-01-28
KR20220154110A (ko) 2022-11-21
US20250195424A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
US20240207365A1 (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
EP1909824B1 (en) Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
US9381247B2 (en) Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US12514907B2 (en) Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes
JP7001584B2 (ja) 安定化されたグルカゴン溶液
HRP20251267T1 (hr) Tekuće formulacije glukagonskih analoga
CN110446496A (zh) 用于治疗糖尿病的系统、组合物和方法
JP2023518052A5 (https=)
JPH0228121A (ja) 経粘膜吸収促進剤及びこれを用いた経鼻投与剤
CN101022822A (zh) 生理学活性肽的液体制剂
WO2016069409A1 (en) Parenteral glucagon formulations
US20180271948A1 (en) Methods for Producing Stable Therapeutic Glucagon Formulations in Aprotic Polar Solvents
CA2796567C (en) Composition comprising insulin and herbal oil for transdermal or transmucosal administration
NZ791927B2 (en) Liquid formulations of glucagon analogues
KR101915803B1 (ko) 엑센딘-4 및 miR-26a를 포함하는 비강 내 투여용 항당뇨 조성물
Hermansen Insulin and new insulin analogues, insulin pumps and inhaled insulin in type 1 diabetes
Lautz et al. Biologic Effectiveness of an Insulin Analogue Developed for Oral Insulin Delivery
CN103655468A (zh) 一种促胰岛素分泌肽融合蛋白Exendin-4-HSA溶液稳定制剂